FAQ: Clene Inc.'s CNM-Au8 Preclinical Data for Parkinson's Disease
Summary
Clene Inc. presented new preclinical data showing its investigational therapy CNM-Au8 improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a Parkinson's disease model. These findings, supported by the Michael J. Fox Foundation and conducted with the Salk Institute, demonstrate CNM-Au8's potential as a neuroprotective therapy for both familial and sporadic Parkinson's disease.
What is CNM-Au8 and what does it do?
CNM-Au8 is an investigational first-in-class therapy developed by Clene Nanomedicine that improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress. It is designed to treat neurodegenerative diseases including Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis.
What specific benefits did CNM-Au8 show in the Parkinson’s disease model?
In the preclinical study, CNM-Au8 improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a dopaminergic neuron model of Parkinson’s disease. The therapy also corrected metabolic imbalances, normalized dysregulated gene expression, and exhibited a favorable safety profile with no toxicity observed in PD neurons.
Who conducted this research and where was it presented?
The research was conducted by Clene Inc. in collaboration with the Salk Institute and supported by Michael J. Fox Foundation funding. The findings were presented at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting in New York City.
Why is this research significant for Parkinson’s disease treatment?
This research is significant because it demonstrates CNM-Au8’s potential as a neuroprotective therapy that addresses fundamental cellular dysfunction in Parkinson’s disease. The therapy showed promise for both familial and sporadic forms of the disease by improving mitochondrial health and reducing inflammation, which are key pathological features.
What is Clene Inc. and what is their focus?
Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
Where can I find more information about this research?
The full press release can be viewed at https://ibn.fm/B9Coc. For more information about Clene Inc., visit www.clene.com or follow them on X (formerly Twitter) and LinkedIn. Latest news and updates relating to CLNN are available at https://ibn.fm/CLNN.
What types of Parkinson’s disease could CNM-Au8 potentially treat?
Based on the preclinical data, CNM-Au8 shows potential as a neuroprotective therapy for both familial and sporadic forms of Parkinson’s disease. The study demonstrated effectiveness in improving cellular health across different types of Parkinson’s disease models.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 196133